Introduction
Multiple myeloma (MM) is a B cell neoplasm characterized by atypical plasma cell infiltration into bone marrow (BM) and monoclonal gammopathy (M-proteinemia). There appears to be an ordered progression to myeloma cells from terminally differentiated B cells (ie plasma cells). The first stage is thought to be monoclonal gammopathy of undetermined significance (MGUS) where the cells may be immortalized but not transformed. Subsequent additional oncogenic events, such as alterations of ras and p53 genes, lead to stepwise malignant transformation of plasma cells, resulting in progression to aggressive MM through the indolent phase (indolent myeloma; IMM). 1 In fulminant phase, tumor cells frequently proliferate outside the medulla or are leukemic in nature (plasma cell leukemia, PCL). p16 INK4A is one of the cyclin-dependent kinase inhibitors (CDKIs) and acts as a negative cell cycle regulator. 2 A gene encoding p16 INK4A protein was discovered at the chromosomal locus 9p21 in which frequent allelic losses have been observed in various malignancies. 3 The p16 INK4A gene is thought to be a potent tumor suppressor gene (TSG) because of its negative effect on the cell cycle, and in fact, frequent structural alterations of the p16 INK4A gene, ie homozygous deletions and point mutations, have been demonstrated in various malignancies. 4, 5 The chromosomal locus 9p21 also contains the gene encoding p14 ARF , which is an alternatively spliced form of p16, and the twin gene p15 INK4B within a distance of approximately 25 kb. 3, 6 The p15 INK4B gene is also thought to be a TSG because of its function as a CDKI and frequent structural alterations in some malignancies. 5 Of the various hematological malignancies, frequent structural alterations of the p16 INK4A and p15 INK4B genes are limited to lymphoid malignancies, especially acute lymphoid leukemia and some malignant lymphomas. 4, 5, 7 However, such alterations have seldom been found in MM despite its status as a lymphoid malignancy. 8, 9 DNA methylation of CpG islands in the promoter region is known to lead to epigenetic gene inactivation by transcriptional silencing. 10 DNA methylation normally occurs in selected imprinted genes 11 and genes on the inactive X-chromosome of females, 12 and may play an important role during normal embryonic development. Since the functional significance of promoter hypermethylation would be the same as loss-of-function types of point mutation and deletion, DNA methylation may be able to affect the expression of TSG and be involved in carcinogenesis. 13, 14 Recent studies have demonstrated frequent hypermethylation of p16 INK4A and p15
INK4B
genes, even in malignancies showing rare structural alterations of these genes. [15] [16] [17] In MM, frequent hypermethylation of these genes has been demonstrated in clinical samples, [18] [19] [20] and their inactivation by hypermethylation was confirmed in cell lines, 21 suggesting an important role of this epigenetic change in the tumorigenesis of MM.
Close relationships between alterations in TSG and disease progression have been reported. 22, 23 p16 INK4A gene alterations may be associated with progression of B cell lymphoma, 24 adult T cell leukemia/lymphoma 25 and childhood acute lymphoblastic leukemia, 26 whereas p15 INK4B gene hypermethylation may be associated with progression to overt leukemia from myelodysplastic syndrome 27, 28 and with poor prognosis of acute leukemias. 29 On the other hand, it was recently reported that aberrant hypermethylation of the p16 INK4A gene was frequently detected in precursor lesions to lung cancers and may be a potential biomarker for early diagnosis. 30 MM is also thought to proceed through different stages as described above. Although frequent aberrant hypermethylation of p16 INK4A and p15 INK4B genes in aggressive MM has been demonstrated, 18, 19 it has not yet been clarified when this aberrant methylation occurs during the development of PCD. To answer this question, we performed methylation analyses of p16 INK4A and p15 INK4B genes focused on the early stages of MM, ie MGUS and IMM.
Leukemia

Methods
Patient profiles and preparation of DNA
We analyzed a total of 105 patients with plasma cell dyscrasias (PCDs) referred to ours and affiliated hospitals. According to the diagnostic criteria for PCD reported by Durie and Salmon, 31 they were diagnosed and divided as follows: 38 patients with MM, 21 with IMM, 33 with MGUS, eight with Waldenströ m macroglobulinemia (WM) and five with polyclonal gammopathy. Patients with smoldering myeloma were included into the IMM group defined by the following criteria: absent or only limited bone lesions, no compression fractures, low paraprotein levels and no symptoms or associated disease features. There were no patients with solitary plasmacytoma among these cases. As controls, samples obtained from patients with aplastic anemia (AA) and healthy volunteers (HV) were analyzed for aberrant methylation. Purified normal B cells of the spleen excised from a patient with gastric cancer were also analyzed. 32 Samples were obtained after obtaining informed consent. Bone marrow mononuclear cells (BMMNCs) were available from 63 patients. Plasmacytoma or peripheral blood (PB) were also available in some patients. Sequential analyses at two different time points were possible in eight patients. MNCs were separated by Ficoll-Paque (Pharmacia, Uppsala, Sweden) density gradient centrifugation. Polymorphonuclear cells (PMNs) and T lymphocytes were obtained as described previously. 33 DNA and RNA extraction from these samples and cell lines (U937, Raji, HL60 and ML1) was performed by the standard procedure. 34 We used BM smears from the other 36 patients. Before DNA extraction, we confirmed that all samples contained at least 2% plasma cells, even in MGUS. DNA from BM smears was extracted using a Nucleon HT kit (Amersham, Buckinghamshire, UK) according to the manufacturer's protocol. DNAs extracted from BM smears were amplified with primer sets for ␤-actin and p16
INK4A genes (Table 1) , respectively, to check their integrity.
Methylation-specific PCR (MSP)
DNA methylation was analyzed by MSP. MSP was performed essentially as described by Herman et al, 35 and consisted of three steps: chemical modification by sodium bisulfite, PCR amplification and gel electrophoresis. We modified aliquots of 500 ng of DNA extracted from clinical samples and cell lines with sodium bisulfite using a DNA modification kit (CpGenome DNA Modification Kit; Oncor, Gaithersburg, MD, USA) according to the manufacturer's instructions. Aliquots of 25 ng of modified DNA were added to 20 l of PCR solution containing 1× PCR buffer (TaKaRa, Kyoto, Japan), dNTP mixture (0.25 mm of each), 5% dimethylsulfoxide and 200 pmol of primer sets specific for unmethylated (U-) or methylated (M)-DNA. For PCR amplification of p15 INK4B gene U-DNA, we used the PCR buffer described by Quesnel et al. 28 After denaturation at 95°C for 5 min, PCR amplification was 'hot started' with 1 unit of Taq DNA polymerase (TaKaRa). PCR conditions are shown in Table 1 . BM-MNC samples were analyzed by 35 cycles of p16-MSP and 40 cycles of p15-MSP. BM smear samples were analyzed by 40 cycles of p16-MSP. PCR products were confirmed by electrophoresis in 11% polyacrylamide gels. Subsequently, we measured the intensity of the methylated and unmethylated bands with Bio max 1D (Eastman Kodak, New Haven, CT, USA) to evaluate the methylation intensity.
To check the qualitative and quantitative abilities of the MSP assay in this study, we prepared cell lines (U937, HL60, ML1) and made a series of mixed samples. In U937 and ML1, p16 INK4A and p15 INK4B gene promoters were completely methylated, respectively, whereas these genes were unmethylated in HL60. 16 For p16-MSP, U937 and HL60 were mixed at ratios of 100:0, 80:20, 60:40, 50:50, 40:60, 20:80, 10:90, 1:99, 0.1:99.9 and 0:100. For p15-MSP, ML1 and HL60 were mixed at similar ratios. DNAs extracted from these mixed samples were modified and subsequently amplified under the same conditions (Table 1 ). These PCR amplifications were repeated at least three times to check the variability. To verify p16-MSP using DNAs from smear samples, we compared the results obtained using BM smears (with and without Giemsa staining) with those using BM-MNCs from two patients. Each modified DNA was amplified with p16-specific primers by 40 cycles of PCR under the conditions shown in Table 1 .
Methylation intensity of each sample was calculated as M/U ratio and evaluated as (−), (+−), (+) or (++) referring to the M/U ratio of samples mixed with methylated and unmethylated DNA of the cell lines described above. The criteria were as follows: (++), M/U ratio above that of the sample with methylated and unmethylated DNA mixed at a ratio 10:90; (+), between those of samples mixed at ratios of 1:99 and 10:90; (+−), less than that of the sample mixed at a ratio of 1:99; (−), no methylation band.
Southern blotting analyses
Southern blotting was performed essentially as described previously. 7, 27 For the p16 INK4A gene, 5 g aliquots of DNA were digested with EcoRI (New England Biolabs, Beverly, MA, USA) and SacII (New England Biolabs), and were also digested with HindIII (Boehringer Mannheim, Mannheim, Germany) and Eco52I (TaKaRa) for the p15 INK4B gene. Digested genomic DNA was separated by electrophoresis through 0.7% agarose gels, and blotted on to nylon membranes (Hybond N; Amersham). The probes produced with the primers as shown in Table 1 were used for detection of the double digested fragments of the p15 INK4B and p16 INK4A genomic DNA. The probe was labeled with ␣-32 P dCTP by the random primer method, and hybridization was performed for 2 h at 65°C using Rapidhyb buffer (Amersham). After washing at high stringency with 0.1× SSC and 0.1% SDS at 65°C, membranes were exposed to phosphor imaging plates (Imaging plate BAS III; Fuji, Japan), which were subsequently studied with a laser image analyzer (Fujix BAS2000; Fuji, Japan).
RT-PCR analyses
Complementary DNA was produced by the standard procedure, 36 and we subsequently amplified the p16
INK4A
, p15 INK4B and ␤-actin genes with each primer set as shown in Table 1 . PCR products were confirmed by electrophoresis in 11% polyacrylamide gels. 35 and PE1 probe was described by Merlo et al.
Results
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Figure 1
Methylation analyses of p16 INK4A and p15 INK4B genes. (a) p16-and p15-methylation-specific PCR (MSP) using mixtures of unmethylated and completely methylated cell lines. For p16-MSP, unmethylated HL60 and completely methylated U937 were mixed at various ratios, whereas for p15-MSP unmethylated HL60 and completely methylated ML1 were mixed. U, PCR products amplified with primers specific for unmethylated DNA; M, PCR products amplified with primers specific for methylated DNA. (Figure 1a) . Thus, the MSP method used in this study was sufficiently sensitive to detect a small methylated population in a large unmethylated population but was not quantitative for analysis of samples containing large amounts of methylated DNA.
The results of p16-MSP obtained using BM smear samples were similar to those obtained using BM-MNC samples irrespective of Giemsa staining (Figure 1b) . Thus, p16-MSP using BM smears was a reliable approach to analyze DNA methylation.
Methylation analyses for control samples
We analyzed methylation status of the p16 INK4A or p15 
MSP for BM-MNC samples
BM-MNC samples were available for a total of 63 patients (MGUS 10, IMM 12, MM 37, WM four, Table 2 ). Thirty-two of these patients (51%) showed methylation bands in p16-MSP ( Figure 3 ). As methylation intensities varied between individuals, we evaluated them as (−) to (++) as described above. The M/U ratios of samples with methylated and unmethylated DNA mixed at a ratio 10:90 and 1:99 are shown in Figure 4 . As shown in Figure 4a and Figure 5 , weak methylation was observed in some patients regardless of diagnosis. However, apparent methylation of the p16 INK4A gene was limited to patients with myeloma. Apparent hypermethylation (++ or +) of the p16 INK4A gene was observed in 15 of 37 patients (41%) with MM, but in only two of 22 patients (9%) with indolent PCD (IMM) (Figures 4a and 5) . The M/U ratios of patients with MM were significantly higher than those of patients with indolent PCD (t-test, P = 0.0055). The M/U ratio was not correlated with % plasma cells in BM. The correlation coefficients were 0.173 and 0.337 in patients with MM and all patients, respectively.
We also analyzed BM-MNC samples for hypermethylation of the p15 INK4B gene. Although methylation bands were visible in some patients, most were weak and apparent hypermethylation of the p15 INK4B gene was only observed in five patients with MM and one patient with IMM (Figures 3 and 4b) .
Four patients with WM did not show apparent hypermethylation of the p16 INK4A or p15 INK4B gene (data not shown). Methylation status in some patients of each category was also analyzed by Southern blotting. All results of Southern blotting were compatible with those of MSP (data not shown).
MSP for BM smear samples
We performed additional analyses using BM smears to increase the number of available PCD and to confirm that hypermethylation of p16 INK4A gene is infrequent in indolent PCD ( 3.1 g/smear) although five extracted DNAs were excluded because of their poor quality of DNA. p16-MSP was performed for 40 cycles to increase the sensitivity because the proportion of plasma cells to total cells may be low. With the exception of one patient with MGUS and one patient with WM, none of the patients showed apparent methylation of the p16 INK4A gene ( Figure 5 ). Two patients with polyclonal gammopathy (plasma cells (PC) 4.7% and 6.7%, respectively) had an unmethylated p16 INK4A gene. As controls, BM smears obtained at the same time as BM-MNC were also analyzed in some myeloma patients. p16-MSP using BM smears showed frequent aberrant methylation, similarly to the results using BM-MNC (data not shown).
Sequential analyses for methylation status
Sequential analyses were possible in eight patients. Our MSP method could not detect significant changes in methylation status of the p16 INK4A We analyzed the changes in methylation status during disease progression in three patients (UPN 79, 85 and 98). Patient 79 developed to MM from IMM in 5 months, but the unmethylated status of the p16 INK4A gene was retained even at MM. Patient 85 showed a significant change in methylation status during disease progression. At initial presentation, he was diagnosed as IMM because of M-proteinemia and a minimal bone lesion. After 2 months, multiple bone lesions had appeared with severe lumbago, indicating disease progression to aggressive MM. Methylation analyses at that time showed newly appearing hypermethylation of the p16 INK4A gene (data not shown). He died of the disease 1 year after first presentation despite chemotherapy. Patient 98 developed to extramedullary plasmacytoma (extra-PC), as described later in detail. BM-MNC at presentation and relapse did not show apparent methylation of the p16 INK4A gene. However, extra-PC at relapse showed densely methylation of the p16 INK4A gene ( Figure 6A ).
Inactivation of the p16 INK4A gene and the development to extra-PC
Since the frequency of extra-PC was high in patients with dense methylation of the p16 INK4A gene (Table 3) , we analyzed showed multiple bone lesions without extra-PC (% plasma cells in BM, 51.5%). His M-protein was gradually reduced by treatment with melphalan and prednisolone. Eight months after initial presentation, he relapsed with an increase in level of M-protein and the growth of a subcutaneous mass on the right chest, pathologically diagnosed as plasmacytoma. Unexpectedly, % plasma cells in BM was decreased (13.0%) and bone scintigram showed improvement of the bone lesions at that time. As shown in Figure 6Aa , BM-MNC had extremely slight methylation of the p16 INK4A gene and apparent methylation of the p15 INK4B gene at initial presentation. Interestingly, extra-PC showed densely methylated status of these genes in contrast to the unmethylated status in BM-MNC even though these samples were obtained at the same time. He died of acute crisis of chronic obstructive pulmonary disease after combination chemotherapy at 5 months after relapse. Samples at autopsy showed similar results as those at relapse (% plasma cells in BM, 11.0%). These differences of methylation status between extra-PC and BM were also confirmed by Southern blotting (data not shown). As shown in Figure 6Ab , RT-PCR demonstrated that levels of expression of these genes were decreased by promoter hypermethylation.
Discussion
Both Southern blotting [18] [19] [20] and MSP 19 analyses of clinical samples from patients with MM have demonstrated frequent aberrant hypermethylation of p16 INK4A and p15 INK4B genes. However, most of the patients analyzed in these previous studies were diagnosed as having MM according to the diagnostic criteria of Durie and Salmon, 31 and patients diagnosed as having IMM have not yet been analyzed in sufficient detail. Therefore, we examined PCD including indolent types, ie IMM and MGUS, to clarify the correlations between aberrant methylation of p16 INK4A and p15 INK4B genes and disease progression. As we used non-purified cells in this study, the (Table 3) .
In contrast, p16 INK4A hypermethylation was significantly infrequent (2/22, 9%) in indolent PCD. Only one patient with IMM (UPN 102) just after progression from MGUS had dense (++) methylation. Interestingly, he subsequently developed to aggressive MM within 1 year. Since it is possible that BM-MNC of indolent PCD did not contain abnormal plasma cells in numbers as high as those in aggressive MM, the frequency of p16 INK4A hypermethylation may have been underestimated in indolent PCD. However, the result was also confirmed on BM smear samples (1/29, 3%). Since 40 cycles of p16-MSP had high sensitivity as shown in Figure 1a , a small methylated population in BM smears would have been detected by this
